Vasopeptidase inhibition improves insulin sensitivity and endothelial function in the JCR:LA-cp rat

Journal of Cardiovascular Pharmacology

Volumn 44, Issue 2, 2004, Pages 258-265

  Russell, James C ^a   Kelly, Sandra E ^a   Schäfer, Stefan ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

ACE inhibitors; AVE7688; Endothelial function; Insulin resistance; JCR:LA cp rat; Ramipril

Indexed keywords

ACETYLCHOLINE; AVE 7688; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; NITROPRUSSIDE SODIUM; RAMIPRIL; UNCLASSIFIED DRUG; VASOPEPTIDASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME INHIBITION; FLOW RATE; HYPERINSULINEMIA; HYPOINSULINEMIA; INHIBITION KINETICS; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; VASCULAR ENDOTHELIUM; VASCULAR RING; VASODILATATION;

ACETYLCHOLINE; ADMINISTRATION, ORAL; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANIMALS, GENETICALLY MODIFIED; AORTA, THORACIC; BLOOD GLUCOSE; BODY WEIGHT; BRADYKININ; DIET; DISEASE MODELS, ANIMAL; EATING; ENDOTHELIUM, VASCULAR; FASTING; HEART; HEART RATE; HETEROCYCLIC COMPOUNDS, 3-RING; INSULIN; INSULIN RESISTANCE; MALE; MUSCLE, SMOOTH, VASCULAR; NEPRILYSIN; NG-NITROARGININE METHYL ESTER; NITROPRUSSIDE; OBESITY; ORGAN SIZE; PHENYLEPHRINE; RAMIPRIL; RATS; VASOCONSTRICTION; VASODILATION;

EID: 3242790173     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200408000-00016     Document Type: Article

References (35)

1. Steiner G. Hyperinsulinemia and hypertriglyceridemia. J Int Med. 1994; 736(suppl):23-26.
2. Després J-P, Lamarche B, Mauriège P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334: 952-957.
3. O'Brien SF, Russell JC. Insulin resistance and vascular wall function: lessons from animal models (Review). Endocrinol Metab. 1997;4:155-162.
4. HOPE Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-259.
5. Molinaro G, Rouleau JL, Adam A. Vasopeptidase inhibitors: a new class of dual zinc metallopeptidase inhibitors for cardiorenal therapeutics. Curr Opin Pharmacol. 2002;2:131-141.
6. Quaschning T, d'Uscio LV, Shaw S, et al. Vasopeptidase inhibition restores renovascular endothelial dysfunction in salt-induced hypertension. J Am Soc Nephrol. 2001;12:2280-2287.
7. Schäfer S, Steioff K, Linz W, et al. Chronic vasopeptidase inhibition normalizes diabetic endothelial dysfunction. Eur J Pharmacol. 2004;484: 361-362.
8. Taal MW, Nenov VD, Wong W, et al. Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone. J Am Soc Nephrol. 2001;12:2051-2059.
9. Davis BJ, Johnston CI, Burrell LM, et al. Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy. Diabetologia. 2003;46:961-971.
10. Schäfer S, Linz W, Bube A, et al. Vasopeptidase inhibition prevents nephropathy in Zucker diabetic fatty rats. Cardiovasc Res. 2003;60:447-454.
11. Kostis JB, Packer M, Black HR, et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004;17:103-111.
12. Koletsky S. Obese spontaneously hypertensive rats: a model for the study of atherosclerosis. Exp Mol Pathol. 1973;19:53-60.
13. Russell JC, Graham S, Hameed M. Abnormal insulin and glucose metabolism in the JCR:LA-corpulent rat. Metabolism. 1994;43:538-543.
14. Russell JC, Koeslag DG, Amy RM, et al. Plasma lipid secretion and clearance in the hyperlipidemic JCR:LA-corpulent rat. Arteriosclerosis. 1989; 9:869-876.
15. Wu-Peng XS, Chua SC Jr, Okada N, et al. Phenotype of the obese Koletsky (f) rat due to Tyr763Stop mutation in the extracellular domain of the leptin receptor. Diabetes. 1997;46:513-518.
16. Russell JC, Graham SE, Richardson M. Cardiovascular disease in the JCR:LA-cp rat. Mol Cell Biochem. 1998;188:113-126.
17. Russell JC, Bar-Tana J, Shillabeer G, et al. Development of insulin resistance in the JCR:LA-cp rat: role of triacylglycerols and effects of MEDICA 16. Diabetes. 1998;47:770-778.
18. Russell JC, Graham SE, Dolphin PJ. Glucose tolerance and insulin resistance in the JCR:LA-cp rat: effect of miglitol (Bay m 1099). Metabolism. 1999;48:701-706.
19. Vance JE, Russell JC. Hypersecretion of VLDL, but not HDL, by hepatocytes from the JCR:LA-corpulent rat. J Lipid Res. 1990;31:1491-15011.
20. Elam MB, Wilcox HG, Cagen LM, et al. Increased hepatic VLDL secretion, lipogenesis, and SREBP-1 expression in the corpulent JCR:LA-cp rat. J Lipid Res. 2001;42:2039-2048.
21. Absher PM, Schneider DJ, Russell JC, et al. Increased proliferation of explanted vascular smooth muscle cells: a marker presaging atherogenesis. Atherosclerosis. 1997;131:187-194.
22. Absher PM, Schneider DJ, Baldor LC, et al. The retardation of vasculopathy induced by attenuation of insulin resistance in the corpulent JCR:LA-cp rat is reflected by decreased vascular smooth muscle cell proliferation in vivo. Atherosclerosis. 1999;143:245-251.
23. Russell JC, Dolphin PJ, Graham SE, et al. Improvement of insulin sensitivity and cardiovascular outcomes in the JCR:LA-cp rat by D-fenfluramine. Diabetologia. 1998;41:380-389.
24. Russell JC, Graham SE, Dolphin PJ, et al. Antiatherogenic effects of long-term benfluorex treatment in male insulin resistant JCR:LA-cp rats. Atherosclerosis. 1997;132:187-197.
25. Russell JC, Amy RM, Manickavel V, et al. Prevention of myocardial disease in the JCR:LA-corpulent rat by running. J Appl Physiol. 1989;66: 1649-1655.
26. Russell JC, Amy RM, Graham SE, et al. Inhibition of atherosclerosis and myocardial lesions in the JCR:LA-cp rat by β,β′ -tetramethylhexadecanedioic acid (MEDICA 16). Arterioscler Thromb Vasc Biol. 1995;15:918-923.
27. Russell JC, McKendrick JD, Dubé GP, et al. Effects of LY 117018 and the estrogen analogue, 17α-ethinylestradiol, on vascular reactivity, platelet aggregation, and lipid metabolism in the insulin-resistant JCR:LA-cp rat: role of nitric oxide. J Cardiovasc Pharmacol. 2001;37:119-128.
28. Russell JC, Amy RM, Dolphin PJ. Effect of n-3 fatty acids on atherosclerosis prone JCR:LA-corpulent rats. Exp Mol Pathol. 1991;55:285-293.
29. De Lean A, Munson PJ, Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol. 1978;235:E97-102.
30. Russell JC, Ravel D, Pégorier J-P, et al. Beneficial insulin-sensitizing and vascular effects of S15261 in the insulin-resistant JCR:LA-cp rat. J Pharmacol Exp Ther. 2000;295:753-760.
31. Brindley DN, Russell JC. Animal models of insulin resistance and cardiovascular disease: some therapeutic approaches using the JCR:LA-cp rat (Invited review). Diab Obes Metab. 2002;4:1-10.
32. Russell JC, Graham SE, Amy RM, et al. Inhibition of myocardial lesions in the JCR:LA-corpulent rat by captopril. J Cardiovasc Pharmacol. 1998; 31:971-977.
33. Wang CH, Leung N, Lapointe N, et al. Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats. Circulation. 2003;107:1923-1929.
34. Pederson RA, Campos RV, Buchan AMJ, et al. Comparison of the entero-insular axis in two strains of obese rats: the fatty Zucker and the JCR:LA-corpulent. Int J Obes. 1991;15:461-470.
35. Richardson M, Schmidt AM, Graham SE, et al. Vasculopathy and insulin resistance in the JCR:LA-cp rat. Atherosclerosis. 1998;138:135-146.